295 related articles for article (PubMed ID: 31494078)
1. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy.
Suvarna V; Singh V; Murahari M
Eur J Pharmacol; 2019 Nov; 862():172655. PubMed ID: 31494078
[TBL] [Abstract][Full Text] [Related]
2. Mimicking the BH3 domain to kill cancer cells.
Ni Chonghaile T; Letai A
Oncogene; 2008 Dec; 27 Suppl 1(0 1):S149-57. PubMed ID: 19641500
[TBL] [Abstract][Full Text] [Related]
3. BH3 mimetics: status of the field and new developments.
Billard C
Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
[TBL] [Abstract][Full Text] [Related]
4. Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
Yu L; Liu S
Semin Cancer Biol; 2013 Dec; 23(6 Pt B):553-60. PubMed ID: 24012660
[TBL] [Abstract][Full Text] [Related]
5. BCL-2: Long and winding path from discovery to therapeutic target.
Schenk RL; Strasser A; Dewson G
Biochem Biophys Res Commun; 2017 Jan; 482(3):459-469. PubMed ID: 28212732
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic inhibition of BCL-2 and related family members.
Levy MA; Claxton DF
Expert Opin Investig Drugs; 2017 Mar; 26(3):293-301. PubMed ID: 28161988
[TBL] [Abstract][Full Text] [Related]
7. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
8. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
Tse C; Shoemaker AR; Adickes J; Anderson MG; Chen J; Jin S; Johnson EF; Marsh KC; Mitten MJ; Nimmer P; Roberts L; Tahir SK; Xiao Y; Yang X; Zhang H; Fesik S; Rosenberg SH; Elmore SW
Cancer Res; 2008 May; 68(9):3421-8. PubMed ID: 18451170
[TBL] [Abstract][Full Text] [Related]
9. Targeting BCL-2-like Proteins to Kill Cancer Cells.
Cory S; Roberts AW; Colman PM; Adams JM
Trends Cancer; 2016 Aug; 2(8):443-460. PubMed ID: 28741496
[TBL] [Abstract][Full Text] [Related]
10. Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members.
Opferman JT
FEBS J; 2016 Jul; 283(14):2661-75. PubMed ID: 26293580
[TBL] [Abstract][Full Text] [Related]
11. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
[TBL] [Abstract][Full Text] [Related]
12. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors.
Ashkenazi A; Fairbrother WJ; Leverson JD; Souers AJ
Nat Rev Drug Discov; 2017 Apr; 16(4):273-284. PubMed ID: 28209992
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?
Labi V; Grespi F; Baumgartner F; Villunger A
Cell Death Differ; 2008 Jun; 15(6):977-87. PubMed ID: 18369371
[TBL] [Abstract][Full Text] [Related]
14. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening.
Enyedy IJ; Ling Y; Nacro K; Tomita Y; Wu X; Cao Y; Guo R; Li B; Zhu X; Huang Y; Long YQ; Roller PP; Yang D; Wang S
J Med Chem; 2001 Dec; 44(25):4313-24. PubMed ID: 11728179
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
Zheng CH; Yang H; Zhang M; Lu SH; Shi D; Wang J; Chen XH; Ren XH; Liu J; Lv JG; Zhu J; Zhou YJ
Bioorg Med Chem Lett; 2012 Jan; 22(1):39-44. PubMed ID: 22172701
[TBL] [Abstract][Full Text] [Related]
16. The chemical biology of apoptosis: Revisited after 17 years.
Yang S; Mao Y; Zhang H; Xu Y; An J; Huang Z
Eur J Med Chem; 2019 Sep; 177():63-75. PubMed ID: 31129454
[TBL] [Abstract][Full Text] [Related]
17. Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy.
Hartman ML; Czyz M
Anticancer Agents Med Chem; 2012 Oct; 12(8):966-81. PubMed ID: 22263800
[TBL] [Abstract][Full Text] [Related]
18. Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy.
Yamaguchi R; Lartigue L; Perkins G
Pharmacol Ther; 2019 Mar; 195():13-20. PubMed ID: 30347215
[TBL] [Abstract][Full Text] [Related]
19. The BCL-2 arbiters of apoptosis and their growing role as cancer targets.
Adams JM; Cory S
Cell Death Differ; 2018 Jan; 25(1):27-36. PubMed ID: 29099483
[TBL] [Abstract][Full Text] [Related]
20. BH3 mimetics inhibit growth of chondrosarcoma--a novel targeted-therapy for candidate models.
Morii T; Ohtsuka K; Ohnishi H; Mochizuki K; Yoshiyama A; Aoyagi T; Hornicek FJ; Ichimura S
Anticancer Res; 2014 Nov; 34(11):6423-30. PubMed ID: 25368242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
